Renal decline after Lu-PSMA-617 not clearly worse than chemotherapy

A propensity score-matched study compared renal function decline in metastatic castration-resistant prostate cancer patients treated with Lu-PSMA-617 versus taxane-based chemotherapy. The study reported no significant difference in early (6-month) eGFR decline between groups, and over longer follow-up, renal decline was significantly greater only in patients with pre-existing chronic kidney disease, not those with preserved baseline renal function. The authors state that renal function decline in this population may not be solely attributable to Lu-PSMA-617 therapy.

Most relevant for: Patients with metastatic castration-resistant prostate cancer, particularly those with chronic kidney disease, being considered for Lu-PSMA-617 radiopharmaceutical therapy or taxane chemotherapy.

Summary written by an AI model from the source text and dated by the source's publication date. Check the original before acting on it. How MedFollow selects and summarizes updates.

Informational only. Not medical advice. Not a substitute for clinical judgment. Always consult current guidelines and your own clinical judgment.